Table 1.
Demographic and Clinical Characteristics of Study Participants, Stratified by Immune Response to the First Dose of SARS-CoV-2 mRNA Vaccine
| Overall (n=123) | Detectable antibody (n=91) | Undetectable antibody (n=32) | p-value1 | |
|---|---|---|---|---|
| Age, median (IQR) | 50 (41, 61) | 46 (37, 61) | 57 (43, 68) | 0.06 |
| Female sex, no. (%) | 117 (95) | 87 (96) | 30 (94) | 0.7 |
| Non-white, no. (%) | 12 (10) | 11 (12) | 1 (3) | 0.2 |
| Diagnosis, no. (%) | ||||
| Inflammatory arthritis2 | 34 (28) | 29 (32) | 5 (16) | 0.5 |
| Systemic lupus erythematous | 24 (20) | 16 (18) | 8 (25) | |
| Sjogren’s syndrome | 16 (13) | 12 (13) | 4 (12) | |
| Myositis | 7 (6) | 4 (4) | 3 (9) | |
| Vasculitis | 2 (2) | 1 (1) | 1 (3) | |
| Overlap3 | 35 (29) | 25 (27) | 10 (31) | |
| Other | 5 (4) | 4 (4) | 1 (3) | |
| Therapy, no. (%) | ||||
| None | 34 (28) | 28 (31) | 6 (19) | 0.5 |
| Non-biologic DMARD4 | 23 (19) | 16 (18) | 7 (22) | |
| Biologic DMARD5 | 17 (14) | 11 (12) | 6 (19) | |
| Corticosteroid-monotherapy6 | 4 (3) | 4 (4) | 0 (0) | |
| Combination therapy | 45 (37) | 32 (35) | 13 (41) |
1
Comparing the detectable antibody group to the undetectable antibody group.
2
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis and inflammatory bowel disease associated arthritis
3
Overlap denotes a combination of 2 or more of the above conditions, also includes systemic sclerosis
4
Azathioprine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine, tacrolimus
5
Adalimumab, certolizumab, etanercept, infliximab, tocilizumab, ustekinumab, ixekizumab, belimumab, rituximab, tofacitinib, abatacept
6
Prednisone and prednisone equivalents